InsidersTradesSigma
Sotera Health Co Stock: price and management transactions · United States · SEC (Form 4)
Follow the Sotera Health Co stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Sotera Health Co has published 83 insider filings. Market capitalisation: €5.2bn. The latest transaction was disclosed on 27 May 2026 (Attribution). Among the most active insiders: Petras Michael B. Jr.. Every trade is openly available.
83
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€2bn
12 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Sotera Health Co Buy (bullish), based on 9 analysts. Average price target: US$20.22.
43Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 13,465 of 26,034 companies
50.9
score / 100
Value42
Quality60
FCF yld2.8%
Earn yld1.5%
EV/EBITDA17.1x
ROE23%
Gross mgn55%
Net mgn6.7%
Debt/EBITDA5.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 27 May 2026
Declarations83 total
14,970 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0001193125-26-242237:0
14,970 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0001193125-26-242188:0
14,970 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0001193125-26-242231:0
19,102,952 shares@ US$15.1684.93% mcap25.0% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0001999371-26-010903:0
12,735,301 shares@ US$15.1683.29% mcap50.0% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0001193125-26-227029:0
19,102,952 shares@ US$15.1684.93% mcap25.0% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0001999371-26-010899:0
7,941 shares@ US$14.3450.0% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0001193125-26-140422:0
12,000,000 shares@ US$15.1117.8% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0001999371-25-012975:0
27,990 shares@ US$12.4711.1% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-25-032994:0
8,211 shares@ US$12.47100.0% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-25-032826:0
3,687 shares@ US$12.471.4% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-25-032831:0
6,481 shares@ US$12.4743.9% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-25-032829:0
29,250 shares@ US$13.2112.0% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-130309:0
2,889 shares@ US$13.211.2% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-130298:0
200,000 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-105933:0
10,000,000 shares@ US$15.0322.1% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0001999371-24-011707:0
15,000,000 shares@ US$15.0310.2% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0001999371-24-011716:0
15,000,000 shares@ US$15.0310.2% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0001999371-24-011715:0
7,659 shares@ US$14.2256.1% of flowCommon Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-092827:0
20,089 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-066037:0
20,089 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-066013:0
20,089 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-066027:0
20,089 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-065968:0
20,089 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-066007:0
20,089 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-065973:0
25 of 83 declarations
About Sotera Health Co
Sotera Health Co (Nasdaq: SHC) is a U.S.-based healthcare services company focused on mission-critical sterilization, laboratory testing, and advisory services for medical-device, pharmaceutical, and broader healthcare customers. The company is listed on the NASDAQ market in the United States (United States), and its corporate headquarters is in Broadview Heights, Ohio. In practical terms, Sotera Health sits at an essential point in the healthcare supply chain: it helps customers meet stringent safety, quality, and regulatory requirements that are difficult to replicate in-house. ([investors.soterahealth.com](https://investors.soterahealth.com/static-files/50a6a4b6-cb76-4bff-861d-0c21a4875633?utm_source=openai)) The group operates through three main platforms. Sterigenics provides industrial sterilization solutions, including gamma irradiation, E-beam, and ethylene oxide services, supporting the sterilization of medical devices and other healthcare products. Nordion is a key supplier of cobalt-60, the isotope used in gamma sterilization, giving the company a strategically important role in the sterilization ecosystem. Nelson Labs offers microbiological testing, validation, and advisory services that help manufacturers qualify products and demonstrate compliance. Together, these businesses create an integrated offering spanning capacity, source material, and laboratory expertise. ([investors.soterahealth.com](https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-reports-fourth-quarter-and-full-year-2024-results/?utm_source=openai)) From an industry perspective, Sotera Health benefits from a relatively defensive profile. Demand is supported by healthcare consumption, recurring customer relationships, and the fact that sterilization and testing services are essential and highly regulated. Barriers to entry are meaningful because they depend on specialized assets, technical expertise, customer qualification, and regulatory approvals. The company has emphasized its role as a provider of “mission-critical end-to-end sterilization solutions” and lab services, which underscores the durability of its market position. ([investors.soterahealth.com](https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-chairman-and-ceo-presents-43rd-annual-jp-morgan?utm_source=openai)) Sotera Health is more international than its Ohio headquarters might suggest. Its customers operate across North America, Europe, and other healthcare manufacturing hubs, so the business is tied to global medical-device and pharmaceutical supply chains. That geographic spread is important because sterilization and testing capacity often needs to be close to manufacturing sites, while sourcing and compliance needs are global. ([investors.soterahealth.com](https://investors.soterahealth.com/static-files/50a6a4b6-cb76-4bff-861d-0c21a4875633?utm_source=openai)) On recent developments, the company reported full-year 2024 results, highlighted another year of top-line growth, and provided 2025 guidance. In February 2025, management said revenues for 2024 were expected to be about $1.1 billion, reflecting roughly 5% growth year over year, and the company later reported 2024 revenue of $1.100 billion. More recently, in February 2026, Sotera Health announced that its board expanded from eleven to twelve directors and appointed a new board member, which is a notable governance update. For investors, the main themes remain steady revenue growth, operational optimization, and ongoing monitoring of legal and regulatory matters that are relevant to the business model. ([investors.soterahealth.com](https://investors.soterahealth.com/news-releases/news-release-details/sotera-health-chairman-and-ceo-presents-43rd-annual-jp-morgan?utm_source=openai))
